Targeted Radionuclide Therapies since 2004

Since ITM Isotopen Technologien München AG was founded in 2004, the idea from the start was to develop and produce next generation radionuclides for tumor therapy. To achieve this, we have been working closely with the Technical University of Munich (TUM) on a range of projects. Over the years, we have been able to set up a very high quality product platform, and to produce innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals under GMP conditions, specially designed for Targeted Radionuclide Therapy in the field of Precision Oncology. Thus, ITM was already a pioneer in Theranostics, right from the outset. 

In 2007 the subsidiary ITG Isotope Technologies Garching GmbH was founded, with the aim of developing and producing medical radionuclides. The initial development of the therapeutic radioisotope 90Y was followed by the production of the 188W/188Re and 225Ac/213Bi Generator. 

In 2009 a start was made on the development of the therapeutic radioisotope n.c.a. 177Lu. In 2010 the production of a new generation, non-metallic 68Ge/68Ga Generator for the diagnostics of tumors with 68Ga through molecular imaging using PET/CT/MR was started. 

In the following years, ITG developed all the equipment and consumables required for the use and processing of diagnostic and therapeutic radionuclides. In addition to the radio-HPLC, this includes different labeling modules.

Because of its long-term experience in the field of radiochemistry, oncology, and receptor-based technology, ITM today offers a first-class, seamlessly integrated product portfolio of radionuclides meeting the highest standards. ITM thus functions as a “one-stop shop” in the field of Targeted Radionuclide Therapies as well as for research purposes. Based on the platform technology that we have created, we are now taking the next strategic step from being purely a provider of radionuclides to being a radiopharmaceutical enterprise. We are currently working on the development of drug candidates in different clinical stages, thereby creating a growing product portfolio of targeting molecules and therapies in the field of Precision Oncology. 

ITM Group Milestones